NEWS

Avanzcare quickly becoming a significant player in MENA healthcare and well-placed for a successful 2017

Avanzcare quickly becoming a significant player in MENA healthcare and well-placed for a successful 2017

First major agreements signed with international partners.

US$35 billion MENA healthcare market expected to grow by a CAGR of approximately 6-9% between 2014 and 2019.

read more
Avanzcare TRACE Certified

Avanzcare TRACE Certified

AVANZCARE is proud to announce it has successfully completed TRACEcertification, an internationally recognized due diligence review.

read more
FDA Approves Flublok® Quadrivalent Influenza Vaccine

FDA Approves Flublok® Quadrivalent Influenza Vaccine

Protein Sciences announced that the FDA has approved its Quadrivalent formulation of Flublok® influenza vaccine.

read more
Avanzcare and Mindray Sign Exclusive Distribution Agreement

Avanzcare and Mindray Sign Exclusive Distribution Agreement

Avanzcare and Mindray have announced a new distribution agreement. Under the two-year agreement, Avanzcare will be the sole distributor of Mindray's life support products in Qatar.

read more
Avanzcare is ISO 9001: 2015 Certified

Avanzcare is ISO 9001: 2015 Certified

As part of its commitment to guarantee the utmost quality to its customers, Avanzcare is now certified as ISO 9001:2015.

read more
Avanzcare and Protein Sciences Announce Licensing of Influenza  Vaccines for the MENA Region

Avanzcare and Protein Sciences Announce Licensing of Influenza Vaccines for the MENA Region

Avanzcare is now the exclusive distributor of Protein influenza vaccines for the Middle East and North Africa markets.

read more
FLUBLOK® to be distributed by Avanzcare in the MENA region.

FLUBLOK® to be distributed by Avanzcare in the MENA region.

FLUBLOK®is the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease.

read more
;